{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-kidney-disease/prescribing-information/ace-inhibitors-aiiras/","result":{"pageContext":{"chapter":{"id":"a270530d-7db1-5b03-a1d8-8ff38e242ab9","slug":"ace-inhibitors-aiiras","fullItemName":"ACE-inhibitors and AIIRAs","depth":2,"htmlHeader":"<!-- begin field 295e7ac5-65f7-4c25-9428-a9f300e8030b --><h2>ACE-inhibitors and AIIRAs</h2><!-- end field 295e7ac5-65f7-4c25-9428-a9f300e8030b -->","summary":"","htmlStringContent":"<!-- begin item 719a2828-ca5f-46b4-aa5c-a9f300e802af --><!-- end item 719a2828-ca5f-46b4-aa5c-a9f300e802af -->","topic":{"id":"cf2598e6-fd50-5f3b-8ae0-aad8ebd19ed8","topicId":"ae266062-cc1b-44e2-8118-44e1890750e3","topicName":"Chronic kidney disease","slug":"chronic-kidney-disease","lastRevised":"Last revised in May 2020","chapters":[{"id":"5036566c-74da-5f5a-8ad0-52200f66bacc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b4e7fb9-e75e-5183-b93f-5121d902b8aa","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75479619-9bb3-51b1-8d45-322a0183327c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"85bf4dec-7d92-5c07-9468-68fd460fa54c","slug":"changes","fullItemName":"Changes"},{"id":"e9caee39-e4d7-55ea-bba5-d1bfb037fab3","slug":"update","fullItemName":"Update"}]},{"id":"94be5ea4-6a52-53bd-9cff-cbc58599fb38","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"af9d912d-8cc7-598f-90cf-201a0152486f","slug":"goals","fullItemName":"Goals"},{"id":"e04a2acd-d3aa-5b29-afe8-4ff8a5cf2527","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c36c8ae1-59b3-5370-8b7b-c879c1c25d17","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb64e97-bb95-5733-ba72-d5da80477d5b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0cefa383-4a3f-5e37-8c1d-0cc7b2ba971c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c308ef71-7be3-579d-9b92-dd1e9164c74d","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"34f1f543-1b43-52aa-91e6-43d392ace4b2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"420f2db7-0bb3-5f08-a35d-671ffd9e83db","slug":"definition","fullItemName":"Definition"},{"id":"f36e5c98-76d5-563f-b7e3-a8e580d8edda","slug":"causes","fullItemName":"Causes"},{"id":"16745b88-79f5-5576-a0a4-704c8cb342e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82584375-f9fb-5690-9fe3-f2fb2586f2de","slug":"complications","fullItemName":"Complications"},{"id":"6ddacff5-19b6-5342-b340-25aecbf26dbd","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00dbd4ad-decc-5bde-b4a3-2599d730c702","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"cdd9f22d-7a2f-5fd6-a9e1-199b0c3ffdfa","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c6b6c8c3-633d-5062-9804-7b6711e7ddcd","slug":"assessment","fullItemName":"Assessment"},{"id":"3878fa85-9973-5158-8407-20d64dbf148d","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"579baee5-96e6-5639-a5ee-7dc30540dc8f","fullItemName":"Management","slug":"management","subChapters":[{"id":"07ec0bcd-8fb7-5ae7-87fd-2ff471574c5c","slug":"management-of-chronic-kidney-disease","fullItemName":"Scenario: Management of chronic kidney disease"},{"id":"44ceaa7d-a91b-5472-a7ab-e4bc448067ad","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"b0158ce5-7a78-50df-8843-ded7d59d08e3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a270530d-7db1-5b03-a1d8-8ff38e242ab9","slug":"ace-inhibitors-aiiras","fullItemName":"ACE-inhibitors and AIIRAs"}]},{"id":"50985320-3b22-5997-85d2-680285318de6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"168ee77d-eb0d-52d8-a32b-4bda877d21f0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c8ca80a7-ccf2-5a42-9b8e-72783e1f2131","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fe26a3ba-fa1b-5c97-8a08-e1f7d193447a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"854a26b2-4877-59ae-863e-99abcbcad667","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0af4d212-648e-5a4d-ad67-b1874a49688e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f180e32d-a855-558d-b666-d4c6804afe04","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ba009e6c-4065-55da-b6c5-bd179af81374","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b0158ce5-7a78-50df-8843-ded7d59d08e3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d6afc1d5-4640-57c3-9da2-457180716a1d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4f637a37-fb70-40ca-9266-a9f300e844a8 --><h3>Contraindications and cautions</h3><!-- end field 4f637a37-fb70-40ca-9266-a9f300e844a8 -->","summary":"","htmlStringContent":"<!-- begin item 7590c1e3-ac95-44a5-8855-a9f300e84489 --><!-- begin field 168f36b0-49ca-4f40-8252-a9f300e844a8 --><ul><li><p><strong>Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in people:</strong></p><ul><li>With a history of angio-oedema associated with previous exposure to an ACE-inhibitor.</li><li>With hereditary or recurrent angio-oedema.</li><li>With diabetes mellitus, or with an eGFR less than 60 mL/min/1.73m<sup>2</sup> who are also taking aliskiren.</li><li>Who are pregnant women or those planning a pregnancy — may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported. Treatment with an ACE-inhibitor should ideally be stopped as soon as pregnancy is detected and, if appropriate, alternative treatment should be started. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> and <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</li><li>Who are breastfeeding women — ACE-inhibitors are not recommended as there is limited information on their safety, and there are insufficient data to exclude a possible risk of profound neonatal hypotension, particularly in preterm babies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">MHRA, 2014b</a>].</li></ul></li><li><strong>ACE-inhibitors should be used with caution in people:</strong><ul><li>Of black African or Caribbean origin, or with primary aldosteronism — may respond less well to ACE-inhibitors.</li><li>With renal impairment — hyperkalaemia and other adverse effects are more common, and the dose may need to be reduced. </li><li>Taking diuretics.</li><li>With peripheral arterial disease or generalised artherosclerosis — due to risk of clinically silent renovascular disease.</li><li>With primary aldosteronism — may respond less well to ACE-inhibitors.</li><li>With hypertrophic cardiomyopathy.</li><li>With severe or symptomatic aortic stenosis — due to risk of hypotension.</li><li>With collagen vascular disease — possible increased risk of agranulocytosis. Full blood count test monitoring is recommended.</li><li>Note: people taking multiple or high-dose diuretics, on a low-sodium diet, on dialysis, who are dehydrated, have unstable heart failure, have known renovascular disease, or hyponatraemia (sodium less than 130 mmol/L), hypotension (systolic blood pressure below 90 mmHg), or hypovolaemia may be more likely to experience first dose hypotension. Specialist advice and/or close supervision when starting treatment may be needed.</li></ul></li><li><strong>Use of angiotensin-II receptor antagonists (AIIRAs) is contraindicated in people:</strong><ul><li>With diabetes mellitus, or with an eGFR less than 60 mL/min/1.73m<sup>2</sup>, who are also taking aliskiren.</li><li>Who are pregnant women or those planning a pregnancy — may adversely affect fetal and neonatal blood pressure control and renal function; neonatal skull defects and oligohydramnios have also been reported. Treatment with an AIIRA should ideally be stopped as soon as pregnancy is detected and, if appropriate, alternative treatment should be started. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> and <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</li><li>Who are breastfeeding women — AIIRAs are not recommended as there is limited information on their safety, and the effects of potential exposure on a breastfeeding infant are unknown [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">MHRA, 2014b</a>].</li></ul></li><li><strong>AIIRAs should be used with caution in people:</strong><ul><li>Of black African or Caribbean origin or with primary aldosteronism — may respond less well to AIIRAs.</li><li>With renal impairment —  hyperkalaemia and other adverse effects are more common, and the dose may need to be reduced. </li><li>With renal artery stenosis.</li><li>With a history of angio-oedema.</li><li>With hypertrophic cardiomyopathy.</li><li>With aortic or mitral valve stenosis.</li><li>In older age groups — lower initial doses may be appropriate.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 168f36b0-49ca-4f40-8252-a9f300e844a8 --><!-- end item 7590c1e3-ac95-44a5-8855-a9f300e84489 -->","subChapters":[]},{"id":"9794b54b-5de0-5a98-be8b-8e9ce250b615","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 72251471-5f5e-4b7b-a4eb-a9f300e87db0 --><h3>Adverse effects</h3><!-- end field 72251471-5f5e-4b7b-a4eb-a9f300e87db0 -->","summary":"","htmlStringContent":"<!-- begin item 8fddc647-702a-4bb2-b1ca-a9f300e87d8d --><!-- begin field 07e822cb-f1c6-4eba-80a2-a9f300e87db0 --><p><strong>Angiotensin-converting enzyme (ACE) inhibitors are generally well tolerated, but occasionally adverse effects can occur. The adverse effect profile of angiotensin-II receptor antagonists (AIIRAs) is similar, although they tend to be milder.</strong></p><ul><li><strong>Possible adverse effects of ACE-inhibitors include:</strong><ul><li>Renal impairment — monitor renal function 1–2 weeks after starting an ACE-inhibitor, after each dose increase, and regularly throughout treatment.</li><li>Hyperkalaemia — monitor serum electrolytes 1–2 weeks after starting an ACE-inhibitor, after each dose increase, and regularly throughout treatment.</li><li>Cough — occurs in about 15% of people taking an ACE-inhibitor, and may occur at any time after starting treatment. If troublesome (for example, affecting sleep) and other causes have been excluded, consider switching to an AIIRA which do not inhibit the breakdown of bradykinin and other kinins, and thus are less likely to cause persistent dry cough.</li><li>Angio-oedema — ACE-inhibitors can cause a non-allergic drug reaction which can precipitate angio-oedema. If suspected, stop ACE-inhibitor treatment immediately, and consider starting an alternative medication. If possible, avoid AIIRAs as these can also trigger episodes. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>Orthostatic hypotension — may present with dizziness, lightheadedness, and headaches, and occurs most commonly in people who are hypovolaemic or hyponatraemic. If symptomatic, consider stopping or reducing the dose of ACE-inhibitor.</li><li>Abdominal discomfort, alopecia, arrhythmias, palpitations, constipation, dyspepsia, diarrhoea, nausea and vomiting, rash, myalgia, muscle spasms, dyspnoea, chest pain, fatigue, tinnitus, and vertigo.</li><li>Hepatic impairment (rare) — stop treatment if marked elevation of hepatic enzymes or jaundice occur.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 07e822cb-f1c6-4eba-80a2-a9f300e87db0 --><!-- end item 8fddc647-702a-4bb2-b1ca-a9f300e87d8d -->","subChapters":[]},{"id":"64f75948-4e57-5483-8b17-e0d3241ba6f6","slug":"dose-regimens","fullItemName":"Dose regimens","depth":3,"htmlHeader":"<!-- begin field 0ebbbbfe-e2fa-48f2-b49c-a9f300e8912b --><h3>Dose regimens</h3><!-- end field 0ebbbbfe-e2fa-48f2-b49c-a9f300e8912b -->","summary":"","htmlStringContent":"<!-- begin item fc1e78ba-2c74-4042-8d20-a9f300e89110 --><!-- begin field 6e2709dc-f260-4da1-8999-a9f300e8912b --><p><strong>Start with a low-dose of angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II receptor antagonist (AIIRA), and gradually titrate upwards (usually every 2–4 weeks depending on the drug) until the person has reached the maximum advised or tolerated dose.</strong></p><ul><li>Measure serum creatinine, estimated glomerular filtration rate (eGFR), and electrolytes before starting treatment<ul><li>If serum potassium is greater than 5 mmol/L, do not start treatment with an ACE-inhibitor or AIIRA.</li></ul></li><li>Advise the person to take the first dose in the evening. If the drug is well tolerated, subsequent doses should be taken in the morning.</li><li>Measure serum creatinine, eGFR, potassium, and blood pressure 1–2 weeks after each upward titration.<ul><li>If there is a decrease in eGFR or increase in serum creatinine after starting or increasing the dose of renin-angiotensin system antagonist but it is less than 25% of baseline eGFR, or 30% of baseline serum creatinine, repeat the test in 1–2 weeks. Do not modify the renin-angiotensin system antagonist dose if the change in eGFR is less than 25% or the change in serum creatinine is less than 30%.</li><li>If the change in baseline eGFR is 25% or more, or the change in baseline serum creatinine is 30% or more, investigate for other causes of a deterioration in renal function, such as volume depletion or concomitant nephrotoxic drugs such as nonsteroidal anti-inflammatory drugs, and if no additional cause is found, stop the renin-angiotensin system antagonist or reduce to a previously tolerated lower dose and recheck levels in 5–7 days. Add an alternative antihypertensive medication if required. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a> for more information.</li><li>If serum potassium is 5.0 mmol/L or above:<ul><li>Investigate for other causes of hyperkalaemia and treat accordingly.</li><li>Stop or reduce the dose of potassium-sparing diuretics (amiloride, triamterene, spironolactone) or nephrotoxic drugs.</li></ul></li><li>If serum potassium is persistently 5.0–5.9 mmol/L despite these measures, reduce the dose of renin-angiotensin system antagonist to a previously tolerated lower dose and recheck levels in 5–7 days.</li><li>Stop the renin-angiotensin system antagonist if serum potassium persists above 6 mmol/L despite these measures.</li></ul></li><li>Details of starting doses, maintenance and maximum doses of ACE-inhibitors are given in Table 1.</li></ul><p><strong>Table 1.</strong> Low starting, usual starting, maintenance, and maximum doses of ACE- inhibitors used for hypertension.</p><table><thead><tr><th scope=\"col\">ACE-inhibitor</th><th scope=\"col\">Low starting doses*</th><th scope=\"col\">Usual starting dose</th><th scope=\"col\">Usual maintenance dose</th><th scope=\"col\">Maximum dose</th></tr></thead><tbody><tr><td>Captopril</td><td>6.25 mg to 12.5 mg single dose, then 6.25 to 12.5 mg twice a day</td><td>12.5 to 25 mg twice a day</td><td>50 to 75 mg twice a day</td><td>75 mg twice a day</td></tr><tr><td>Enalapril</td><td>2.5 mg once a day</td><td>5 mg once a day</td><td>20 mg once a day</td><td>40 mg once a day</td></tr><tr><td>Fosinopril</td><td>10 mg once a day</td><td>10 mg once a day</td><td>10 to 40 mg once a day</td><td>40 mg once a day</td></tr><tr><td>Imidapril</td><td>2.5 mg once a day</td><td>5 mg once a day</td><td>10 mg once a day</td><td>20 mg once a day</td></tr><tr><td>Lisinopril</td><td>2.5 mg once a day</td><td>10 mg once a day</td><td>20 mg once a day</td><td>80 mg once a day</td></tr><tr><td>Perindopril arginine</td><td>2.5 mg once a day</td><td>5 mg once a day</td><td>5 to 10 mg once a day</td><td>10 mg once a day</td></tr><tr><td>Quinapril</td><td>2.5 mg once a day</td><td>10 mg once a day</td><td>10 to 20 mg twice daily</td><td>40 mg twice daily</td></tr><tr><td>Ramipril</td><td>1.25 mg once a day</td><td>1.25 to 2.5 mg once a day</td><td>2.5 mg to 10 mg once a day</td><td>10 mg once a day</td></tr><tr><td>Trandolapril</td><td>500 micrograms once a day</td><td>500 micrograms once a day</td><td>1 to 2 mg once a day</td><td>4 mg once a day</td></tr><tr><td colspan=\"5\">* Lower starting doses are required for people who are more prone to the adverse effects of ACE-inhibitors (such as the elderly, frail, or people taking diuretics).</td></tr><tr><td colspan=\"5\"><strong>Information from:  </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Joint Formulary Committee, 2019</a>]</td></tr></tbody></table><p><strong>Table 2.</strong> Low starting, usual starting, maintenance, and maximum doses of AIIRAs used for hypertension.</p><table><thead><tr><th scope=\"col\">ARIIA</th><th scope=\"col\">Low starting doses*</th><th scope=\"col\">Usual starting dose</th><th scope=\"col\">Usual maintenance dose</th><th scope=\"col\">Maximum dose</th></tr></thead><tbody><tr><td>Azilsartan</td><td>20 to 40 mg once a day</td><td>40 mg once a day</td><td>40 to 80 mg once a day</td><td>80 mg once a day</td></tr><tr><td>Candesartan</td><td>4 mg once a day</td><td>8 mg once a day</td><td>8 mg once a day</td><td>32  mg once a day</td></tr><tr><td>Eprosartan</td><td>600 mg once a day</td><td>600 mg once a day</td><td>600 mg once a day</td><td>600 mg once a day</td></tr><tr><td>Irbesartan</td><td>75 mg once a day</td><td>150 mg once a day</td><td>150 mg once a day</td><td>300 mg once a day</td></tr><tr><td>Losartan</td><td>25 mg once a day</td><td>50 mg once a day</td><td>50 mg once a day</td><td>100 mg once a day</td></tr><tr><td>Olmesartan</td><td>10 mg once a day</td><td>10 mg once a day</td><td>20 mg once a day</td><td>40 mg once a day</td></tr><tr><td>Telmisartan</td><td>20 mg once a day</td><td>20 to 40 mg once a day</td><td>40 mg once a day</td><td>80 mg once a day</td></tr><tr><td>Valsartan</td><td>40 mg once a day</td><td>80 mg once a day</td><td>80 to 160 mg once a day</td><td>320 mg once a day</td></tr><tr><td colspan=\"5\">* Lower starting doses are required for people who are more prone to the adverse effects of AIIRAs (such as the elderly, frail, or people taking diuretics).</td></tr><tr><td colspan=\"5\"><strong>Information from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Joint Formulary Committee, 2019</a>]</td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">NICE, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 6e2709dc-f260-4da1-8999-a9f300e8912b --><!-- end item fc1e78ba-2c74-4042-8d20-a9f300e89110 -->","subChapters":[]},{"id":"43869dda-cf73-52c2-81ff-02c9cefa9085","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ca6376fb-f0aa-438c-8588-a9f300e8aad0 --><h3>Drug interactions</h3><!-- end field ca6376fb-f0aa-438c-8588-a9f300e8aad0 -->","summary":"","htmlStringContent":"<!-- begin item 7970b529-b0d3-4453-ac78-a9f300e8aab3 --><!-- begin field 123f52ba-065a-4817-b7ac-a9f300e8aad0 --><p><strong>Possible drug interactions with angiotensin-converting enzyme (ACE) inhibitors include:</strong></p><ul><li>Angiotensin-II receptor antagonists (AIIRAs) and aliskerin — concomitant use of two drugs affecting the renin-angiotensin system increases the risk of hyperkalaemia, hypotension, and renal impairment.</li><li>Diuretics — ACE-inhibitors can cause a very rapid fall in blood pressure in a person who is volume depleted.<ul><li>Treatment should be initiated at very low doses.</li><li>If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE-inhibitor should be intitiated under close supervision and in some cases the diuretic dose may need to be reduced, or the diuretic discontinued at least 24 hours beforehand.</li><li>If high-dose diuretic therapy cannot be stopped, close observation is recommended for at least 2 hours following the first dose of ACE-inhibitor, or until the blood pressure has stablised.</li></ul></li><li>Allopurinol — possible increased risk of leucopenia and hypersensitivity reactions, especially in people with renal impairment.</li><li>Bee/wasp venom extracts — risk of severe anaphylaxis.</li><li>Non-steroidal anti-inflammatory drugs (NSAIDs) — increased risk of renal impairment, and hypotensive effect antagonised with concomitant use.</li><li>Antacids — possible decreased absorption of ACE-inhibitors with use of an antacid.</li><li>Amiloride, eplerenone, heparins, ciclosporin, potassium canrenoate, potassium salts, triamterene, trimethoprim —  increased risk of hyperkalaemia. Monitoring of electrolytes and renal function may be advised.</li><li>Digoxin — concomitant use with captopril can increase plasma concentrations of digoxin. Regular monitoring of plasma digoxin concentration is advised.</li><li>Alpha-blockers, antipsychotics, anxiolytics, beta-blockers, calcium-channel blockers, clonidine, co-beneldopa, co-careldopa, hydralazine, hypnotics, levodopa, methyldopa, minoxidil, moxonidine, nitrates, sodium nitroprusside, tizanidine — enhanced hypotensive effect.</li><li>Insulin, metformin, and sulfonylureas — enhanced hypoglycaemic effect.</li><li>Corticosteroids, oestrogens — hypotensive effect antagonised with concomitant use.</li><li>Lithium — concomitant use can increase plasma levels of lithium. Regular monitoring of serum lithium concentrations is advised.</li><li>Sacubitril — manufacturer advises to avoid concomitant use of lisinopril with sacubitril/valsartan therapy. Lisinopril must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan.</li><li>Ciclosporin — Hyperkalaemia may occur during concomitant use of ACE inhibitors with ciclosporin. </li><li>Heparin — hyperkalaemia may occur during concomitant use of ACE inhibitors with heparin. Monitoring of serum potassium is recommended.</li><li>Spironolactone — increased risk of severe hyperkalaemia. Use lowest possible dose of both drugs and monitor renal function closely.</li></ul><p><strong>Possible drug interactions with AIIRAs include:</strong></p><ul><li>ACE-inhibitors and aliskerin — concomitant use of two drugs affecting the renin-angiotensin system increases the risk of hyperkalaemia, hypotension, and renal impairment.</li><li>Diuretics — prior treatment with high-dose diuretics may result in volume depletion and a risk of hypotension.</li><li>Lithium — reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitoring of serum lithium levels is recommended.</li><li>NSAIDs — attenuation of antihypertensive effect may occur and there may be an increased risk of deteriorating renal function, including possible acute kidney injury and hyperkalaemia. Consider monitoring renal function after starting concomitant therapy, and periodically thereafter, and people should be counselled regarding the importance of adequate hydration.</li><li>Amiloride, ciclosporin, eplerenone, heparins, potassium salts, spironolactone, tacrolimus, trimethoprim — increased risk of hyperkalaemia. Monitoring of electrolytes and renal function may be advised.</li><li>Alpha-blockers, alprostadil, antipsychotics, anxiolytics, beta-blockers, baclofen, calcium-channel blockers, clonidine, co-beneldopa, co-careldopa, hydralazine, hypnotics, levodopa, methyldopa, minoxidil, moxonidine, nitrates, tizanidine — enhanced hypotensive effect.</li><li>Corticosteroids, oestrogens — hypotensive effect antagonised with concomitant use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 123f52ba-065a-4817-b7ac-a9f300e8aad0 --><!-- end item 7970b529-b0d3-4453-ac78-a9f300e8aab3 -->","subChapters":[]},{"id":"05f6922d-0738-5d79-b84d-a7036a5ecd06","slug":"covid-19","fullItemName":"COVID-19","depth":3,"htmlHeader":"<!-- begin field e92b112e-1ede-4989-807f-abc200f3d218 --><h3>COVID-19</h3><!-- end field e92b112e-1ede-4989-807f-abc200f3d218 -->","summary":"","htmlStringContent":"<!-- begin item 59568f40-2000-4121-9552-abc200f3d17f --><!-- begin field e20f7853-2fdd-42ad-b467-abc200f3d218 --><ul><li>People who are taking ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin receptor blocker) medications (also known as AIIRAs) for any indication should not stop taking these drugs during the COVID-19 pandemic, whether they are unaffected by the virus or have contracted the disease.</li><li>The reason for this is that there is no evidence from the limited published literature that taking these medications adversely affects outcomes from COVID-19 or the likelihood of acquiring the infection.</li><li>Stopping the medications, however, is associated with adverse outcomes.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">NICE, 2020b</a>]</p><!-- end field e20f7853-2fdd-42ad-b467-abc200f3d218 --><!-- end item 59568f40-2000-4121-9552-abc200f3d17f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}